MedTrace Logo

The Pharmacokinetics of Azithromycin Prophylaxis for Cesarean Delivery

NCT01464840 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2017-05-11

Study results available
· View outcomes & findings →

Summary

PKAZ is a single institution study designed to evaluate the optimal dosing parameters for azithromycin for pre-surgical cesarean prophylaxis.

Hypothesis: Pre-operative administration of azithromycin results in maternal and neonatal tissue concentrations that adequately treat microbes commonly involved in post-cesarean infections.

Conditions

  • Endometritis

Interventions

DRUG

Azithromycin

500 mg intravenous infused over 1 hour

Sponsors & Collaborators

  • University of Alabama at Birmingham

    lead OTHER

Principal Investigators

  • Amelia L Sutton, M.D., Ph.D. · University of Alabama at Birmingham

Eligibility

Min Age
19 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-05-31
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01464840 on ClinicalTrials.gov